{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:26:27Z","timestamp":1712881587937},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue des Maladies Respiratoires"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.rmr.2024.02.014","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T15:31:28Z","timestamp":1709911888000},"page":"317-324","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Complications s\u00e9v\u00e8res des traitements syst\u00e9miques du patient canc\u00e9reux thoracique (complications hors infections et urgences respiratoires)"],"prefix":"10.1016","volume":"41","author":[{"given":"T.","family":"Berghmans","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Brand\u00e3o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ilzkovitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.-P.","family":"Meert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmr.2024.02.014_bib0190","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.rmr.2024.02.014_bib0195","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.rmr.2014.08.001","article-title":"Le patient canc\u00e9reux thoracique aux soins intensifs","volume":"31","author":"Meert","year":"2014","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.rmr.2024.02.014_bib0200","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.rmr.2018.05.014","article-title":"Cancer bronchique\u00a0: le pronostic aux soins intensifs d\u00e9pend principalement de la complication aigu\u00eb","volume":"36","author":"Gorham","year":"2019","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.rmr.2024.02.014_bib0205","first-page":"38","article-title":"A prospective study of febrile neutropenia in lung cancer patients","volume":"2","author":"Berghmans","year":"2007","journal-title":"Hospital Chronicles"},{"key":"10.1016\/j.rmr.2024.02.014_bib0210","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1378\/chest.124.1.114","article-title":"A prospective study of infections in lung cancer patients admitted to the hospital","volume":"124","author":"Berghmans","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2024.02.014_bib0215","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3389\/fmed.2016.00033","article-title":"Continuous renal replacement therapy for acute renal failure in patients with cancer: a well-tolerated adjunct treatment","volume":"3","author":"Fischler","year":"2016","journal-title":"Front Med"},{"key":"10.1016\/j.rmr.2024.02.014_bib0220","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s00134-021-06508-w","article-title":"Critically ill cancer patient's resuscitation: a Belgian\/French societies\u2019 consensus conference","volume":"47","author":"Meert","year":"2021","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.rmr.2024.02.014_bib0225","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.rmr.2017.08.006","article-title":"Toxicit\u00e9 des inhibiteurs de point de contr\u00f4le immunitaire","volume":"35","author":"Delaunay","year":"2018","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.rmr.2024.02.014_bib0230","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 [Internet]. [cited 2023\u00a0Oct 8]. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf."},{"key":"10.1016\/j.rmr.2024.02.014_bib0235","first-page":"27: 522","article-title":"Toxicit\u00e9s s\u00e9v\u00e8res des immunoth\u00e9rapies du cancer","author":"Campedel","year":"2018","journal-title":"Med Intensive Rea"},{"key":"10.1016\/j.rmr.2024.02.014_bib0240","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1158\/2326-6066.CIR-16-0237","article-title":"Comprehensive meta-analysis of key immune-related adverse events from CTLA-4\u00a0and PD-1\/PD-L1\u00a0inhibitors in cancer patients","volume":"5","author":"De Velasco","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.rmr.2024.02.014_bib0245","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.rmr.2024.02.014_bib0250","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13613-019-0487-x","article-title":"Severe toxicity from checkpoint protein inhibitors: what intensive care physicians need to know?","volume":"9","author":"Lemiale","year":"2019","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.rmr.2024.02.014_bib0255","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.3390\/cancers14163878","article-title":"Grade 3-4\u00a0immune-related adverse events induced by immune checkpoint inhibitors in non-small-cell lung cancer (NSCLC) patients are correlated with better outcome: a real-life observational study","volume":"14","author":"Guezour","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.rmr.2024.02.014_bib0260","doi-asserted-by":"crossref","first-page":"102134","DOI":"10.1016\/j.ctrv.2020.102134","article-title":"Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - a systematic review and meta-analysis","volume":"92","author":"Hussaini","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.rmr.2024.02.014_bib0265","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13613-023-01122-z","article-title":"ICU admission for solid cancer patients treated with immune checkpoint inhibitors","volume":"13","author":"Toffart","year":"2023","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.rmr.2024.02.014_bib0270","doi-asserted-by":"crossref","first-page":"1700050","DOI":"10.1183\/13993003.00050-2017","article-title":"Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients","volume":"50","author":"Delaunay","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2024.02.014_bib0275","doi-asserted-by":"crossref","first-page":"e2021155","DOI":"10.5826\/dpc.1101a155","article-title":"Cutaneous adverse events of immune checkpoint inhibitors: a literature review","volume":"11","author":"Apalla","year":"2021","journal-title":"Dermatol Pract Concept"},{"key":"10.1016\/j.rmr.2024.02.014_bib0280","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.rmr.2024.02.014_bib0285","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1177\/0885066618787788","article-title":"Management of acute complications of targeted therapy in patients with cancer: a review of cases managed in ICU","volume":"34","author":"Pistone","year":"2019","journal-title":"J Intensive Care Med"},{"key":"10.1016\/j.rmr.2024.02.014_bib0290","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1093\/annonc\/mdu234","article-title":"Intensive care in patients with lung cancer: a multinational study","volume":"25","author":"Soares","year":"2014","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.rmr.2024.02.014_bib0295","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13613-018-0426-2","article-title":"Characteristics and outcome of patients with newly diagnosed advanced or metastatic lung cancer admitted to intensive care units (ICUs)","volume":"8","author":"Barth","year":"2018","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.rmr.2024.02.014_bib0300","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.7150\/jca.18178","article-title":"Outcomes of cancer therapy administered to treatment-na\u00efve lung cancer patients in the intensive care unit","volume":"8","author":"Chen","year":"2017","journal-title":"J Cancer"},{"key":"10.1016\/j.rmr.2024.02.014_bib0305","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0169-5002(02)00219-2","article-title":"Outcome of patients admitted to the intensive care unit with newly diagnosed small cell lung cancer","volume":"38","author":"Jennens","year":"2002","journal-title":"Lung Cancer Amst Neth"},{"key":"10.1016\/j.rmr.2024.02.014_bib0310","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1177\/08850666211061312","article-title":"Outcomes of critically ill lung cancer patients initiating targeted therapy or immunotherapy in the intensive care unit: a single-center report","volume":"37","author":"Lazar Neto","year":"2022","journal-title":"J Intensive Care Med"},{"key":"10.1016\/j.rmr.2024.02.014_bib0315","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s00134-014-3535-x","article-title":"Patients with advanced lung cancer harboring oncogenic mutations should be admitted to intensive care units","volume":"41","author":"Toffart","year":"2015","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.rmr.2024.02.014_bib0320","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1471-2253-14-55","article-title":"The impact of rescue or maintenance therapy with EGFR TKIs for stage IIIb\u2013IV non-squamous non-small-cell lung cancer patients requiring mechanical ventilation","volume":"14","author":"Hsia","year":"2014","journal-title":"BMC Anesthesiol"},{"key":"10.1016\/j.rmr.2024.02.014_bib0325","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.chest.2021.06.079","article-title":"Tyrosine kinase inhibitors for acute respiratory failure because of non-small-cell lung cancer involvement in the ICU","volume":"161","author":"Tandjaoui-Lambiotte","year":"2022","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2024.02.014_bib0330","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.3390\/biomedicines9101416","article-title":"Tyrosine kinase inhibitors improved survival of critically ill EGFR-mutant lung cancer patients undergoing mechanical ventilation","volume":"9","author":"Lee","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.rmr.2024.02.014_bib0335","first-page":"100147","article-title":"Salvage immunotherapy with pembrolizumab in patients hospitalized for life-threatening complications of NSCLC","volume":"2","author":"Roborel de Climens","year":"2021","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.rmr.2024.02.014_bib0340","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.rmr.2023.07.003","article-title":"ICU admission for cancer patients with respiratory failure: an ethical dilemma","volume":"40","author":"Toffart","year":"2023","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.rmr.2024.02.014_bib0345","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy\u201d","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.rmr.2024.02.014_bib0350","doi-asserted-by":"crossref","first-page":"102113","DOI":"10.1016\/j.eclinm.2023.102113","article-title":"Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations","volume":"62","author":"D\u2019Arienzo","year":"2023","journal-title":"ClinicalMedicine"},{"key":"10.1016\/j.rmr.2024.02.014_bib0355","doi-asserted-by":"crossref","first-page":"4852","DOI":"10.1200\/JCO.23.01361","article-title":"Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, phase II DESTINY-Lung02 trial","volume":"41","author":"Goto","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2024.02.014_bib0360","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.3389\/fimmu.2020.01973","article-title":"Neurotoxicity and cytokine release syndrome after chimeric antigen receptor T-Cell therapy: insights into mechanisms and novel therapies","volume":"11","author":"Siegler","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.rmr.2024.02.014_bib0365","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.rmr.2024.02.014_bib0185","doi-asserted-by":"crossref","first-page":"e000604","DOI":"10.1136\/jitc-2020-000604","article-title":"Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy","volume":"8","author":"Haanen","year":"2020","journal-title":"J Immunother Cancer"}],"container-title":["Revue des Maladies Respiratoires"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S076184252400144X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S076184252400144X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T11:48:51Z","timestamp":1712836131000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S076184252400144X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S076184252400144X"],"URL":"https:\/\/doi.org\/10.1016\/j.rmr.2024.02.014","relation":{},"ISSN":["0761-8425"],"issn-type":[{"value":"0761-8425","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complications s\u00e9v\u00e8res des traitements syst\u00e9miques du patient canc\u00e9reux thoracique (complications hors infections et urgences respiratoires)","name":"articletitle","label":"Article Title"},{"value":"Revue des Maladies Respiratoires","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmr.2024.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 SPLF. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}